-
J.
Harvey,
S.
Down,
R.
Bright-Thomas,
J.
Winstanley,
H.
Bishop
(2013)
Breast cancer—facts and figures
-
NCCN clinical practice guidelines in oncology.
-
P.
Munster,
K.
Thurn,
S.
Thomas,
P.
Raha,
M.
Lacevic,
Ashleigh
Miller,
M.
Melisko,
R.
Ismail-Khan,
H.
Rugo,
M.
Moasser,
S.
Minton
(2011)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
British Journal of Cancer, 104
-
S.
Massarweh,
E.
Romond,
E.
Black,
E.
Meter,
B.
Shelton,
Vera
Kadamyan-Melkumian,
M.
Stevens,
R.
Elledge
(2013)
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure
Breast Cancer Research and Treatment, 143
-
E.
Geuna,
A.
Milani,
R.
Martinello,
Caterina
Aversa,
G.
Valabrega,
M.
Scaltriti,
F.
Montemurro
(2015)
Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer
Expert Opinion on Investigational Drugs, 24
-
M.
Mayer,
A.
Hunis,
R.
Oratz,
C.
Glennon,
P.
Spicer,
E.
Caplan,
L.
Fallowfield
(2010)
Living with metastatic breast cancer: a global patient survey
Community oncology, 7
-
R.
Finn,
J.
Crown,
I.
Láng,
K.
Boér,
I.
Bondarenko,
Sergey
Kulyk,
J.
Ettl,
Ravi
Patel,
T.
Pintér,
Marcus
Schmidt,
Y.
Shparyk,
A.
Thummala,
N.
Voytko,
C.
Fowst,
Xin
Huang,
Sindy
Kim,
S.
Randolph,
D.
Slamon
(2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
The Lancet. Oncology, 16 1
-
U.
Dailey
Cancer,Facts and Figures about.
Journal of the National Medical Association, 14 1
-
J.
Baselga,
M.
Campone,
M.
Piccart,
H.
Burris,
H.
Rugo,
T.
Sahmoud,
S.
Noguchi,
M.
Gnant,
K.
Pritchard,
F.
Lebrun,
J.
Beck,
Yoshinori
Ito,
D.
Yardley,
I.
Deleu,
Alejandra
Perez,
T.
Bachelot,
L.
Vittori,
Zhi-Xia
Xu,
P.
Mukhopadhyay,
D.
Lebwohl,
G.
Hortobagyi
(2012)
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
The New England journal of medicine, 366 6
-
(2015)
Ibrance (Palbociclib) Capsules, for Oral Use [Package Insert
-
P.
Fedele,
L.
Orlando,
P.
Schiavone,
N.
Calvani,
C.
Caliolo,
A.
Quaranta,
A.
Nacci,
S.
Cinieri
(2015)
Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer.
Critical reviews in oncology/hematology, 94 3
-
R.
Carlson,
A.
O'neill,
T.
Vidaurre,
H.
Gómez,
S.
Badve,
G.
Sledge
(2012)
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
Breast Cancer Research and Treatment, 133
-
A.
DeMichele,
A.
Clark,
K.
Tan,
D.
Heitjan,
Kristi
Gramlich,
M.
Gallagher,
P.
Lal,
M.
Feldman,
Paul
Zhang,
Christopher
Colameco,
D.
Lewis,
Melissa
Langer,
N.
Goodman,
S.
Domchek,
K.
Gogineni,
M.
Rosen,
K.
Fox,
P.
O'dwyer
(2014)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Clinical Cancer Research, 21
-
J.
Ferlay,
I.
Soerjomataram,
M.
Ervik,
R.
Dikshit,
S.
Eser,
C.
Mathers
(2013)
GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012
-
R.
Chlebowski
(2013)
Changing concepts of hormone receptor-positive advanced breast cancer therapy.
Clinical breast cancer, 13 3
-
A.
Bardia,
S.
Modi,
M.
Gregor,
M.
Kittaneh,
A.
Marino,
A.
Matano,
S.
Bhansali,
B.
Hewes,
J.
Cortés
(2014)
Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
Journal of Clinical Oncology, 32
-
J.
Beck,
G.
Hortobagyi,
M.
Campone,
F.
Lebrun,
I.
Deleu,
H.
Rugo,
B.
Pistilli,
N.
Masuda,
L.
Hart,
B.
Melichar,
S.
Dakhil,
M.
Geberth,
M.
Nunzi,
Daniel
Heng,
T.
Brechenmacher,
M.
El-Hashimy,
S.
Douma,
F.
Ringeisen,
M.
Piccart
(2013)
Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
Breast Cancer Research and Treatment, 143
-
J.
Robertson,
J.
Ferrero,
H.
Bourgeois,
H.
Kennecke,
R.
Boer,
W.
Jacot,
J.
Mcgreivy,
S.
Suzuki,
Min
Zhu,
I.
McCaffery,
E.
Loh,
J.
Gansert,
P.
Kaufman
(2013)
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
The Lancet. Oncology, 14 3
-
B.
Ramaswamy,
W.
Fiskus,
B.
Cohen,
C.
Pellegrino,
D.
Hershman,
E.
Chuang,
T.
Luu,
G.
Somlo,
M.
Goetz,
R.
Swaby,
C.
Shapiro,
V.
Stearns,
P.
Christos,
I.
Espinoza‐Delgado,
K.
Bhalla,
J.
Sparano
(2012)
Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
Breast Cancer Research and Treatment, 132
-
H.
Burstein,
C.
Cirrincione,
W.
Barry,
H.
Chew,
S.
Tolaney,
D.
Lake,
Cynthia
Ma,
K.
Blackwell,
E.
Winer,
C.
Hudis
(2014)
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced brea
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 35
-
A.
Brufsky
(2014)
Managing Postmenopausal Women with Hormone Receptor–Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway
The Breast Journal, 20
-
R.
Finn,
J.
Dering,
D.
Conklin,
O.
Kalous,
David
Cohen,
Amrita
Desai,
C.
Ginther,
M.
Atefi,
I.
Chen,
C.
Fowst,
G.
Los,
D.
Slamon
(2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Breast Cancer Research : BCR, 11
-
J.
O’Shaughnessy
(2005)
Extending survival with chemotherapy in metastatic breast cancer.
The oncologist, 10 Suppl 3
-
A.
Onitilo,
J.
Engel,
R.
Greenlee,
B.
Mukesh
(2009)
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.
Clinical medicine & research, 7 1-2
-
M.
Ellis,
A.
Llombart-Cussac,
D.
Feltl,
J.
Dewar,
M.
Jasiówka,
N.
Hewson,
Y.
Rukazenkov,
J.
Robertson
(2015)
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study
Journal of Clinical Oncology, 33
-
R.
Finn,
M.
Press,
J.
Dering,
L.
O’Rourke,
A.
Florance,
C.
Ellis,
Anne-Marie
Martin,
S.
Johnston
(2013)
Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research, 20
-
J.
Braybrooke
(2013)
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
-
(2000)
National Cancer Institute. Exemestane with or without entinostat in treating postmenopausal patients with recurrent hormone receptor-positive breast cancer that is locally advanced or metastatic
-
Clinical Medicine Insights: Oncology
-
E2112: a randomized phase III trial of endocrine therapy plus entinostat or placebo in patience with hormone receptor-positive advanced breast cancer.
-
M.
Gnant,
J.
Baselga,
H.
Rugo,
S.
Noguchi,
H.
Burris,
M.
Piccart,
G.
Hortobagyi,
J.
Eakle,
H.
Mukai,
H.
Iwata,
M.
Geberth,
L.
Hart,
P.
Hadji,
M.
El-Hashimy,
S.
Rao,
T.
Taran,
T.
Sahmoud,
D.
Lebwohl,
M.
Campone,
K.
Pritchard
(2013)
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
Journal of the National Cancer Institute, 105 9
-
F.
André,
P.
Neven,
N.
Marinsek,
Jie
Zhang,
J.
Baladi,
R.
Degun,
G.
Benelli,
S.
Saletan,
G.
Jerusalem
(2014)
Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
Current Medical Research and Opinion, 30
-
Exemestane with or without entinostat in treating postmenopausal patients with recurrent hormone receptor-positive breast cancer that is locally advanced or metastatic.
-
K.
Pritchard,
H.
Burris,
Yoshinori
Ito,
H.
Rugo,
S.
Dakhil,
G.
Hortobagyi,
M.
Campone,
T.
Csöszi,
J.
Baselga,
P.
Puttawibul,
M.
Piccart,
D.
Heng,
S.
Noguchi,
V.
Srimuninnimit,
H.
Bourgeois,
Antonio
Martín,
K.
Osborne,
A.
Panneerselvam,
T.
Taran,
T.
Sahmoud,
M.
Gnant
(2013)
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Clinical breast cancer, 13 6
-
D.
Zardavas,
J.
Baselga,
M.
Piccart
(2013)
Emerging targeted agents in metastatic breast cancer
Nature Reviews Clinical Oncology, 10
-
M.
Cristofanilli,
V.
Valero,
A.
Mangalik,
M.
Royce,
I.
Rabinowitz,
F.
Arena,
J.
Kroener,
E.
Curcio,
C.
Watkins,
S.
Bacus,
E.
Cora,
Elizabeth
Anderson,
P.
Magill
(2010)
Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer
Clinical Cancer Research, 16
-
K.
Cadoo,
T.
Traina,
T.
King
(2013)
Advances in molecular and clinical subtyping of breast cancer and their implications for therapy.
Surgical oncology clinics of North America, 22 4
-
B.
Moy,
P.
Neven,
F.
Lebrun,
M.
Bellet,
Bing-he
Xu,
T.
Sarosiek,
L.
Chow,
P.
Goss,
C.
Zacharchuk,
E.
Leip,
K.
Turnbull,
N.
Bardy-Bouxin,
L.
Duvillié,
I.
Láng
(2014)
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
The oncologist, 19 4
-
D.
Yardley
(2013)
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions
Breast Cancer : Basic and Clinical Research, 7
-
E.
Mayer
(2015)
Targeting Breast Cancer with CDK Inhibitors
Current Oncology Reports, 17
-
R.
Chlebowski
(2014)
Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer
Clinical investigation, 4
-
V.
Devita,
V.
Devita,
T.
Lawrence,
S.
Rosenberg
(2015)
DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology
-
(2014)
J Clin Oncol
-
M.
Piccart,
G.
Hortobagyi,
M.
Campone,
K.
Pritchard,
F.
Lebrun,
Yoshinori
Ito,
S.
Noguchi,
Alejandra
Perez,
H.
Rugo,
I.
Deleu,
H.
Burris,
L.
Provencher,
P.
Neven,
M.
Gnant,
M.
Shtivelband,
C.
Wu,
Jenna
Fan,
W.
Feng,
T.
Taran,
J.
Baselga
(2014)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 12
-
LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6 – reactivating Rb in cancer.
-
S.
Rothschild
(2014)
microRNA therapies in cancer
Molecular and cellular therapies, 2
-
A.
Macalalad,
Y.
Hao,
Peggy
Lin,
J.
Signorovitch,
E.
Wu,
E.
Ohashi,
Zhou
Zhou,
C.
Kelley
(2015)
Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010)
Current Medical Research and Opinion, 31
-
T.
Bachelot,
C.
Bourgier,
C.
Cropet,
I.
Ray-Coquard,
J.
Ferrero,
G.
Freyer,
S.
Abadie-Lacourtoisie,
J.
Eymard,
M.
Debled,
D.
Spaëth,
E.
Legouffe,
D.
Allouache,
C.
Kouri,
E.
Pujade-Lauraine
(2012)
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 22
-
A.
Leo,
G.
Jerusalem,
L.
Petruželka,
R.
Torres,
I.
Bondarenko,
R.
Khasanov,
D.
Verhoeven,
J.
Pedrini,
I.
Smirnova,
M.
Lichinitser,
K.
Pendergrass,
Sally
Garnett,
J.
Lindemann,
F.
Sapunar,
Miguel
Martín
(2010)
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 30
-
Y.
Chia,
Cynthia
Ma
(2009)
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
Breast Diseases: A Year Book Quarterly, 20
-
W.
Tan,
A.
Dueck,
P.
Flynn,
P.
Steen,
D.
Anderson,
K.
Rowland,
D.
Northfelt,
E.
Perez
(2013)
N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 10
-
D.
Fry,
P.
Harvey,
P.
Keller,
W.
Elliott,
M.
Meade,
E.
Trachet,
M.
Albassam,
Xianxian
Zheng,
W.
Leopold,
N.
Pryer,
P.
Toogood
(2004)
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
Molecular cancer therapeutics, 3 11
-
E.
Mrózek,
R.
Layman,
B.
Ramaswamy,
L.
Schaaf,
Xiaobai
Li,
Susan
Ottman,
C.
Shapiro
(2012)
Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Clinical breast cancer, 12 2
-
D.
Yardley,
R.
Ismail-Khan,
B.
Melichar,
M.
Lichinitser,
P.
Munster,
P.
Klein,
S.
Cruickshank,
K.
Miller,
M.
Lee,
J.
Trepel
(2013)
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 17
-
C.
Villanueva,
G.
Romieu,
J.
Salvat,
L.
Chaigneau,
Y.
Merrouche,
T.
N'guyen,
A.
Vuillemin,
M.
Demarchi,
E.
Dobi,
X.
Pivot
(2013)
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06
Targeted Oncology, 8
-
R.
Riemsma,
Carol
Forbes,
A.
Kessels,
K.
Lykopoulos,
M.
Amonkar,
Daniel
Rea,
Jos
Kleijnen
(2010)
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer
Breast Cancer Research and Treatment, 123
-
S.
Maira,
S.
Pecchi,
A.
Huang,
M.
Burger,
M.
Knapp,
Dario
Sterker,
C.
Schnell,
Daniel
Guthy,
Tobi
Nagel,
M.
Wiesmann,
S.
Brachmann,
C.
Fritsch,
M.
Dorsch,
P.
Chène,
K.
Shoemaker,
A.
Pover,
D.
Menezes,
G.
Martiny-Baron,
D.
Fabbro,
Christopher
Wilson,
R.
Schlegel,
F.
Hofmann,
C.
García-echeverría,
W.
Sellers,
C.
Voliva
(2011)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Molecular Cancer Therapeutics, 11
-
K.
Pritchard,
K.
Gelmon,
D.
Rayson,
L.
Provencher,
M.
Webster,
D.
Mcleod,
S.
Verma
(2013)
Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.
Current oncology, 20 1
-
D.
Pfister,
K.
Ang,
D.
Brizel
(2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
-
A.
Partridge,
R.
Rumble,
L.
Carey,
S.
Come,
N.
Davidson,
A.
Leo,
J.
Gralow,
G.
Hortobagyi,
B.
Moy,
D.
Yee,
S.
Brundage,
M.
Danso,
M.
Wilcox,
I.
Smith
(2014)
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 29
-
A.
Leo,
G.
Jerusalem,
L.
Petruželka,
R.
Torres,
I.
Bondarenko,
R.
Khasanov,
D.
Verhoeven,
J.
Pedrini,
I.
Smirnova,
M.
Lichinitser,
K.
Pendergrass,
L.
Malorni,
Sally
Garnett,
Y.
Rukazenkov,
Miguel
Martín
(2013)
Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial
JNCI Journal of the National Cancer Institute, 106
-
Jennifer
Davis,
Shiaw-Yih
Lin
(2011)
DNA damage and breast cancer.
World journal of clinical oncology, 2 9
-
V.
Guarneri,
D.
Generali,
A.
Frassoldati,
F.
Artioli,
C.
Boni,
L.
Cavanna,
E.
Tagliafico,
A.
Maiorana,
A.
Bottini,
K.
Cagossi,
G.
Bisagni,
F.
Piacentini,
G.
Ficarra,
S.
Bettelli,
E.
Roncaglia,
Simona
Nuzzo,
R.
Swaby,
C.
Ellis,
C.
Holford,
P.
Conte
(2014)
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 10
-
C.
Sanchez,
Cynthia
Ma,
R.
Crowder,
Therese
Guintoli,
C.
Phommaly,
F.
Gao,
Li
Lin,
M.
Ellis
(2011)
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Breast Cancer Research : BCR, 13
-
W.
Anderson,
N.
Chatterjee,
W.
Ershler,
O.
Brawley
(2002)
Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database
Breast Cancer Research and Treatment, 76
-
Su2C phase Ib study of the P13Ka inhibitor BYL19 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
-
(2015)
Available at: http://seer.cancer.gov/statfacts/html/breast.html
-
D.
Yardley,
S.
Noguchi,
K.
Pritchard,
H.
Burris,
J.
Baselga,
M.
Gnant,
G.
Hortobagyi,
M.
Campone,
B.
Pistilli,
M.
Piccart,
B.
Melichar,
K.
Petráková,
F.
Arena,
F.
Erdkamp,
W.
Harb,
W.
Feng,
A.
Cahana,
T.
Taran,
D.
Lebwohl,
H.
Rugo
(2013)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Advances in Therapy, 30
-
Shaloo
Gupta,
Jie
Zhang,
G.
Jerusalem
(2014)
The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective
Expert Review of Pharmacoeconomics & Outcomes Research, 14
-
K.
Cadoo,
A.
Gucalp,
T.
Traina
(2014)
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Breast Cancer : Targets and Therapy, 6
-
Sunkyu
Kim,
Alice
Loo,
R.
Chopra,
G.
Caponigro,
A.
Huang,
S.
Vora,
S.
Parasuraman,
S.
Howard,
N.
Keen,
W.
Sellers,
C.
Brain
(2013)
Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.
Molecular Cancer Therapeutics, 12
-
N.
Turner,
C.
Bartlett,
M.
Cristofanilli
(2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
The New England journal of medicine, 373 17
-
S.
Glück
(2014)
Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action.
Clinical breast cancer, 14 2
-
Lei
Fang,
Z.
Barekati,
Bei
Zhang,
Zhi-yong
Liu,
Xiaoyan
Zhong
(2011)
Targeted therapy in breast cancer: what's new?
Swiss medical weekly, 141
-
Yutaka
Yamamoto,
T.
Ishikawa,
Y.
Hozumi,
M.
Ikeda,
H.
Iwata,
H.
Yamashita,
T.
Toyama,
T.
Chishima,
S.
Saji,
M.
Yamamoto-Ibusuki,
H.
Iwase
(2013)
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
BMC Cancer, 13
-
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
-
A.
West,
R.
Johnstone
(2014)
New and emerging HDAC inhibitors for cancer treatment.
The Journal of clinical investigation, 124 1
-
I.
Mayer,
V.
Abramson,
J.
Balko,
S.
Isakoff,
M.
Kuba,
M.
Sanders,
A.
Forero-Torres,
J.
Yap,
A.
Abbeele,
Yisheng
Li,
C.
Arteaga,
E.
Winer,
Stand
Cancers
(2012)
SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC).
Journal of Clinical Oncology, 30
-
P.
Kawalec,
S.
Łopuch,
Alicja
Mikrut
(2015)
Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Clinical breast cancer, 15 2
-
F.
Cardoso,
E.
Senkus-Konefka,
L.
Fallowfield,
A.
Costa,
M.
Castiglione
(2010)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
-
A.
Bardia,
D.
Haber
(2014)
Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 31
-
Cynthia
Ma,
M.
Ellis
(2007)
Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-Analysis
Breast Diseases: A Year Book Quarterly, 18
-
I.
Mayer,
V.
Abramson,
S.
Isakoff,
A.
Forero,
J.
Balko,
M.
Kuba,
M.
Sanders,
J.
Yap,
A.
Abbeele,
Yisheng
Li,
L.
Cantley,
E.
Winer,
C.
Arteaga
(2014)
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 12
-
S.
Carrick,
Sharon
Parker,
Charlene
Thornton,
D.
Ghersi,
J.
Simes,
N.
Wilcken
(2005)
Single agent versus combination chemotherapy for metastatic breast cancer.
The Cochrane database of systematic reviews, 2
-
A.
Llombart-Cussac,
A.
Ruíz,
A.
Antón,
A.
Barnadas,
S.
Antolín,
J.
Alés‐Martínez,
I.
Álvarez,
R.
Andrés,
J.
Sáenz,
J.
Lao,
E.
Carrasco,
Carmen
Cámara,
Isabel
Casas,
Miguel
Martín
(2012)
Exemestane versus anastrozole as front‐line endocrine therapy in postmenopausal patients with hormone receptor‐positive, advanced breast cancer
Cancer, 118
-
M.
Sharial,
M.
Sharial,
J.
Crown,
B.
Hennessy,
B.
Hennessy
(2012)
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
Annals of Oncology, 23
-
M.
Campone,
T.
Bachelot,
M.
Gnant,
I.
Deleu,
H.
Rugo,
B.
Pistilli,
S.
Noguchi,
M.
Shtivelband,
K.
Pritchard,
L.
Provencher,
H.
Burris,
L.
Hart,
B.
Melichar,
G.
Hortobagyi,
F.
Arena,
J.
Baselga,
A.
Panneerselvam,
A.
Héniquez,
Mona
El-Hashimyt,
T.
Taran,
T.
Sahmoud,
M.
Piccart
(2013)
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
European journal of cancer, 49 12